This multicenter, double-blind, placebo-controlled, dose-response study was conducted in
patients with primary hypercholesterolemia to examine the effects of pravastatin, a selective …

Epidemiological evidence and clinical trials with fibrate therapy show a clear relationship
between low levels of high-density lipoprotein cholesterol (HDL-C) and cardiovascular risk …

Background Statins (3-hydroxy-3-methylglutaryl–coenzyme A [HMG-CoA] reductase
inhibitors) have been used for a decade to lower low-density lipoprotein (LDL) cholesterol …

Background The HMG CoA reductase inhibitors have quickly become the most widely
prescribed family of agents for the treatment of patients with elevated low-density lipoprotein …

This is a comment on" Intensive lipid lowering with atorvastatin in patients with stable
coronary disease." N Engl J Med. 2005 Apr 7; 352 (14): 1425-35. This is a comment on" …

Background: The reduction in plasma LDL-C concentrations with 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitor (statin) therapy has been reported to reduce cardiovascular …

Objective: To investigate the effect of atorvastatin vs simvastatin on lipid profile and plasma
fibrinogen in patients with hypercholesterolaemia. Patients: 30 outpatients (25 men), with a …

Aim. Statins are the drugs of choice in heterozygous famil-ial hypercholesterolemia (FH),
which has a high risk of premature cardiovascular events including myocardial infarction …

Despite the potential for reduced morbidity and mortality, aggressive intervention against
mild to moderate hypercholesterolemia in patients with coronary heart disease (CHD) …

Background Guidelines endorse statin therapy for lowering low-density lipoprotein
cholesterol (LDL-C) to recommended levels, in patients with cardiovascular disease (CVD) …